{
    "hands_on_practices": [
        {
            "introduction": "A core principle in quality improvement is understanding and managing variation in a process. Statistical Process Control (SPC) provides a powerful framework for this, using control charts to distinguish between expected, random fluctuations (common cause) and signals of a fundamental process change (special cause). This first practice focuses on constructing an individuals and moving range ($X\\text{-}MR$) chart, a fundamental tool for monitoring continuous data points collected over time, such as daily length of stay in an emergency department .",
            "id": "5198107",
            "problem": "A pediatric emergency department (ED) quality improvement team is constructing an individuals and moving range chart (commonly denoted $X\\text{-}MR$) to monitor day-to-day variation in patient length of stay. Statistical Process Control (SPC) assumes, under stable conditions, that individual observations are independent and arise from a process with a fixed mean and standard deviation. In the $X\\text{-}MR$ methodology, the center line for the individuals chart is the process mean estimated by the average of the observed $X$ values, and the three-sigma control limits for the individuals chart are based on an estimate of the process standard deviation derived from the average moving range of successive observations. You may assume the constant $d_2$ for a moving range of size $2$ equals $1.128$.\n\nYou are given $12$ consecutive daily observations of pediatric ED length of stay (in hours) as individual values $X$: $3.8, 4.2, 5.1, 4.5, 4.9, 3.7, 4.0, 3.6, 4.4, 4.8, 5.0, 4.1$. The corresponding moving ranges $MR$ (defined as the absolute difference between consecutive $X$ values) are provided for days $2$ through $12$: $0.4, 0.9, 0.6, 0.4, 1.2, 0.3, 0.4, 0.8, 0.4, 0.2, 0.9$.\n\nStarting from the foundational SPC definitions and the properties of moving ranges for normally distributed processes, derive the center line and three-sigma control limits for the individuals chart using these data. Then compute and report the upper control limit for the individuals chart. Express the final value in hours and round your answer to four significant figures.",
            "solution": "The user has provided a problem that is scientifically grounded, well-posed, and objective. The data and constants are sufficient and internally consistent. The problem is a direct application of standard methodologies in Statistical Process Control (SPC), a valid scientific and engineering discipline. Therefore, the problem is deemed valid and a full solution will be provided.\n\nThe objective is to compute the upper control limit (UCL) for an individuals chart ($X$-chart) based on a given set of data. The methodology of an individuals and moving range ($X\\text{-}MR$) chart relies on estimating the process mean and standard deviation from the data.\n\nFirst, we establish the center line (CL) for the individuals chart. The CL is the best estimate of the process mean, which is calculated as the average of the individual observations, $\\bar{X}$.\nLet $X_i$ be the $i$-th observation, for $i = 1, 2, \\dots, N$. The number of observations is $N=12$.\nThe individual observations are: $3.8, 4.2, 5.1, 4.5, 4.9, 3.7, 4.0, 3.6, 4.4, 4.8, 5.0, 4.1$.\n\nThe center line, $\\bar{X}$, is calculated as:\n$$ \\bar{X} = \\frac{1}{N} \\sum_{i=1}^{N} X_i $$\n$$ \\bar{X} = \\frac{3.8 + 4.2 + 5.1 + 4.5 + 4.9 + 3.7 + 4.0 + 3.6 + 4.4 + 4.8 + 5.0 + 4.1}{12} $$\n$$ \\bar{X} = \\frac{52.1}{12} $$\n\nNext, we estimate the process standard deviation, $\\sigma$. In the $X\\text{-}MR$ methodology, this is done using the moving range. The moving range, $MR_i$, is the absolute difference between two consecutive observations: $MR_i = |X_i - X_{i-1}|$ for $i = 2, 3, \\dots, N$.\nThe number of moving ranges is $k = N-1 = 11$. The provided moving ranges are: $0.4, 0.9, 0.6, 0.4, 1.2, 0.3, 0.4, 0.8, 0.4, 0.2, 0.9$.\n\nWe calculate the average moving range, $\\overline{MR}$:\n$$ \\overline{MR} = \\frac{1}{k} \\sum_{i=2}^{N} MR_i $$\n$$ \\overline{MR} = \\frac{0.4 + 0.9 + 0.6 + 0.4 + 1.2 + 0.3 + 0.4 + 0.8 + 0.4 + 0.2 + 0.9}{11} $$\n$$ \\overline{MR} = \\frac{6.5}{11} $$\n\nFor a process that is in a state of statistical control and follows a normal distribution, the expected value of the moving range of size $n=2$ is related to the process standard deviation $\\sigma$ by the constant $d_2$. The relationship is $E(MR) = d_2 \\sigma$. An unbiased estimator for the standard deviation, $\\hat{\\sigma}$, can thus be derived from the average moving range:\n$$ \\hat{\\sigma} = \\frac{\\overline{MR}}{d_2} $$\nThe problem provides the constant $d_2 = 1.128$ for a moving range of size $2$.\nSubstituting the expression for $\\overline{MR}$:\n$$ \\hat{\\sigma} = \\frac{6.5/11}{1.128} $$\n\nThe three-sigma control limits for the individuals chart are defined as:\nCenter Line (CL) $= \\bar{X}$\nUpper Control Limit (UCL) $= \\bar{X} + 3\\hat{\\sigma}$\nLower Control Limit (LCL) $= \\bar{X} - 3\\hat{\\sigma}$\n\nWe are tasked with computing the UCL. We substitute the expressions for $\\bar{X}$ and $\\hat{\\sigma}$:\n$$ UCL = \\bar{X} + 3 \\left( \\frac{\\overline{MR}}{d_2} \\right) $$\nNow, we substitute the numerical values:\n$$ UCL = \\frac{52.1}{12} + 3 \\left( \\frac{6.5/11}{1.128} \\right) $$\n$$ UCL = \\frac{52.1}{12} + \\frac{3 \\times 6.5}{11 \\times 1.128} $$\n$$ UCL = \\frac{52.1}{12} + \\frac{19.5}{12.408} $$\nPerforming the calculations:\n$$ \\bar{X} \\approx 4.341666... $$\n$$ \\frac{19.5}{12.408} \\approx 1.571566... $$\n$$ UCL \\approx 4.341666... + 1.571566... $$\n$$ UCL \\approx 5.913233... $$\n\nThe problem requires the final answer to be rounded to four significant figures. The first four significant figures are $5.913$. The fifth significant digit is $2$, so we round down.\n$$ UCL \\approx 5.913 $$\nThe derived center line is approximately $4.342$ hours, and the upper control limit for the daily patient length of stay is $5.913$ hours.",
            "answer": "$$\\boxed{5.913}$$"
        },
        {
            "introduction": "Quality improvement is an iterative process of learning, driven by the Plan-Do-Study-Act (PDSA) cycle. The 'Study' phase, where we interpret data from a test of change, is critical for making wise decisions about what to do next. This exercise presents a realistic scenario where an initial test did not lead to improvement, challenging you to diagnose the reason by distinguishing between a theory failure and an execution failure .",
            "id": "5198055",
            "problem": "A tertiary children’s hospital aims to increase the proportion of caregivers of admitted children with asthma who can correctly perform metered-dose inhaler with spacer technique during discharge teach-back from a baseline centerline of approximately $44\\%$ to $85\\%$ in $12$ weeks, using the Model for Improvement. The first Plan-Do-Study-Act (PDSA) cycle tested a change on a single general pediatrics team over $2$ weeks: a standardized teach-back using a $5$-step checklist placed in a paper packet, plus a one-page printed leaflet in the discharge folder. Measures were defined a priori as follows:\n\n- Outcome measure: percent of eligible discharges in which the caregiver correctly demonstrates the full technique during teach-back, assessed by a blinded observer using the same $5$-step checklist.\n- Process measure: percent of eligible discharges in which the standardized teach-back was attempted and the $5$-step checklist was completed by the discharging nurse.\n- Balancing measure: mean discharge teaching time per patient (minutes), calculated from timestamps in the Electronic Health Record (EHR; Electronic Health Record).\n\nData over $6$ consecutive weeks (baseline weeks $1$–$4$, PDSA weeks $5$–$6$) are summarized:\n\n- Outcome measure (weekly): $45\\%$, $40\\%$, $47\\%$, $44\\%$, then $43\\%$, $41\\%$.\n- Process measure (weekly): unavailable at baseline; during PDSA weeks $5$–$6$: $21\\%$, $27\\%$ of eligible discharges had the checklist completed.\n- Balancing measure: mean discharge teaching time increased from $14$ minutes at baseline to $17$ minutes during weeks $5$–$6$.\n\nQualitative feedback from $8$ nurses indicated that the checklist was stored in a distant workroom, nurses had not received hands-on practice, and finding the paper tool during discharge was difficult when census was high.\n\nUsing first principles of the Model for Improvement, including the distinction between change theory validity and execution reliability, classify whether this PDSA’s lack of improvement primarily reflects a theory failure or an execution failure, and select the most appropriate next PDSA focus.\n\nA. Execution failure; next test should increase reliability by integrating the $5$-step checklist into the EHR discharge navigator with an automated prompt, provide brief just-in-time training, and test on one team on the next $2$ shifts to raise the process measure before reassessing the outcome.\n\nB. Theory failure; abandon teach-back and immediately switch to a new change idea (pre-discharge video modules for all families) across the unit to seek outcome improvement.\n\nC. Measurement artifact; change the primary outcome to $30$-day readmissions for asthma and expand measurement to all respiratory diagnoses to increase sample size before deciding on next steps.\n\nD. Execution failure; spread the current paper checklist and leaflet hospital-wide to increase exposure and statistical power, then re-evaluate after $8$ more weeks.",
            "solution": "The user has provided a problem in the domain of quality improvement and patient safety science, specifically applying the Model for Improvement to a pediatric asthma education project. The task requires a critical validation of the problem statement, followed by a first-principles derivation of the solution and a detailed evaluation of the provided options.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n*   **Aim:** Increase the proportion of caregivers correctly performing metered-dose inhaler (MDI) with spacer technique from a baseline centerline of approximately $44\\%$ to a goal of $85\\%$ within $12$ weeks.\n*   **Methodology:** Model for Improvement, utilizing Plan-Do-Study-Act (PDSA) cycles.\n*   **PDSA Cycle 1 Change:** A standardized teach-back using a $5$-step paper checklist and a printed leaflet.\n*   **PDSA Cycle 1 Scope:** Tested on a single general pediatrics team over $2$ weeks.\n*   **A Priori Measures:**\n    *   **Outcome Measure:** Percent of eligible discharges where the caregiver correctly demonstrates the full technique.\n    *   **Process Measure:** Percent of eligible discharges where the standardized teach-back was attempted and the $5$-step checklist was completed.\n    *   **Balancing Measure:** Mean discharge teaching time per patient (minutes).\n*   **Quantitative Data:**\n    *   **Outcome Measure (weekly):** Baseline (weeks $1-4$): $45\\%$, $40\\%$, $47\\%$, $44\\%$. PDSA (weeks $5-6$): $43\\%$, $41\\%$.\n    *   **Process Measure (weekly):** Baseline: unavailable. PDSA (weeks $5-6$): $21\\%$, $27\\%$.\n    *   **Balancing Measure:** Baseline mean: $14$ minutes. PDSA weeks $5-6$ mean: $17$ minutes.\n*   **Qualitative Data:** Feedback from $8$ nurses indicated the paper checklist was inaccessible (\"stored in a distant workroom\"), they lacked training (\"had not received hands-on practice\"), and the tool was hard to use under high-stress conditions (\"difficult when census was high\").\n*   **Question:** Classify the lack of improvement as a theory failure or an execution failure and select the most appropriate next PDSA focus.\n\n**Step 2: Validate Using Extracted Givens**\n\n*   **Scientifically Grounded:** The problem is firmly rooted in the established principles of quality improvement science, a rigorous and evidence-based discipline applied in healthcare. The Model for Improvement, PDSA cycles, and the use of outcome, process, and balancing measures are core, non-controversial concepts in this field. The clinical context (asthma education) is a standard focus for patient safety and quality initiatives.\n*   **Well-Posed:** The problem is well-posed. It provides a clear objective, a description of the intervention tested, and specific quantitative and qualitative data from the test. The question asks for an interpretation of these data based on the foundational principles of the stated methodology (distinguishing theory vs. execution failure), which leads to a logical and unique conclusion about the next step.\n*   **Objective:** The problem statement is objective, presenting data and a scenario without subjective or biased language. The question asks for a classification and plan based on \"first principles,\" providing a clear, objective framework for the required analysis.\n\nNo flaws are identified. The problem is a valid, well-constructed case study in applied quality improvement science.\n\n**Step 3: Verdict and Action**\n\nThe problem is valid. The solution process will now proceed.\n\n### Solution Derivation\n\nThe core of this problem lies in correctly interpreting the results of the first PDSA cycle using the fundamental principles of the Model for Improvement. A critical distinction in this methodology is between a **theory failure** and an **execution failure**.\n\n1.  **Defining Theory vs. Execution:**\n    *   A **theory of change** is the underlying hypothesis that a specific change will lead to a desired improvement. In this case, the theory is: \"Standardized teach-back using a $5$-step checklist will improve caregivers' MDI technique.\"\n    *   **Execution** refers to the degree to which the planned change was actually implemented. The **process measure** is designed specifically to quantify this.\n\n2.  **Analysis of Measures:**\n    *   **Outcome Measure:** The baseline data ($45\\%$, $40\\%$, $47\\%$, $44\\%$) establish a stable process with a mean of $\\frac{45+40+47+44}{4} = 44\\%$. During the PDSA cycle, the results were $43\\%$ and $41\\%$. These values fall within the range of a common-cause variation of the baseline. There is no statistically significant improvement; the change, as tested, had no effect on the outcome.\n    *   **Process Measure:** This is the most critical piece of data for interpretation. The process measure, which tracks the completion of the checklist, was only $21\\%$ and $27\\%$ during the PDSA weeks. This means that the intended change (the standardized teach-back with the checklist) was only executed in a small minority of cases. In approximately $75\\%$ of discharges, the intervention did not happen as planned.\n    *   **Balancing Measure:** The teaching time increased by $17 - 14 = 3$ minutes. This is a negative consequence, suggesting the new process, even when attempted, adds burden.\n\n3.  **Connecting the Data and Classifying the Failure:**\n    *   We cannot evaluate the validity of the change theory if the change itself is not being performed. Since the process measure is very low, the team did not successfully execute the intervention. The lack of improvement in the outcome measure is a direct result of the intervention not being implemented.\n    *   Therefore, this is a classic **execution failure**, not a theory failure. The hypothesis that the checklist can improve skills remains untested because the checklist was not used.\n    *   The qualitative feedback from the nurses provides a clear explanation for this execution failure: the paper-based tool was poorly integrated into the workflow, inaccessible, and staff were not trained on its use.\n\n4.  **Determining the Next Appropriate Step:**\n    *   According to the PDSA methodology, when an execution failure is identified, the next step is *not* to abandon the theory. Instead, the next cycle must focus on improving the reliability of the execution. The goal should be to redesign the process to address the barriers identified in the \"Study\" phase.\n    *   The next PDSA cycle should aim to make the process more reliable (increase the process measure) by making it easier for the nurses to perform the change correctly. This involves directly addressing the feedback: making the tool accessible (e.g., integrating into the EHR), providing training, and ensuring it works within the real-world clinical workflow. The test should remain small in scope (e.g., a few shifts, one team) to allow for rapid learning. Only after achieving high reliability on the process measure can the team re-evaluate the outcome measure to test the original theory.\n\n### Option-by-Option Analysis\n\n**A. Execution failure; next test should increase reliability by integrating the $5$-step checklist into the EHR discharge navigator with an automated prompt, provide brief just-in-time training, and test on one team on the next $2$ shifts to raise the process measure before reassessing the outcome.**\n*   **Classification:** Correctly identifies the issue as an **execution failure**, supported by the low process measure.\n*   **Proposed Action:** The proposed next steps directly address the root causes of the execution failure identified in the qualitative data. Integrating the checklist into the EHR solves the accessibility problem (\"distant workroom,\" \"difficult to find\"). Providing just-in-time training addresses the lack of practice. Testing on a small scale (\"one team on the next $2$ shifts\") adheres to the principle of rapid-cycle iteration. The stated goal (\"to raise the process measure before reassessing the outcome\") is the methodologically correct focus.\n*   **Verdict:** **Correct**.\n\n**B. Theory failure; abandon teach-back and immediately switch to a new change idea (pre-discharge video modules for all families) across the unit to seek outcome improvement.**\n*   **Classification:** Incorrectly classifies the problem as a **theory failure**. This conclusion is unsupported because the theory was never adequately tested due to poor execution.\n*   **Proposed Action:** Abandoning the current idea is premature. Switching to a completely new idea represents \"solution jumping\" rather than iterative, sequential learning. Implementing it \"across the unit\" is an inappropriate scaling of an untested idea, violating the core PDSA principle of small-scale testing.\n*   **Verdict:** **Incorrect**.\n\n**C. Measurement artifact; change the primary outcome to $30$-day readmissions for asthma and expand measurement to all respiratory diagnoses to increase sample size before deciding on next steps.**\n*   **Classification:** Incorrectly attributes the result to a **measurement artifact**. There is no evidence that the measurement system is flawed. The lack of change in the outcome is explained by the low process adherence, not a faulty measurement.\n*   **Proposed Action:** Changing the outcome to $30$-day readmissions is inadvisable for a rapid-cycle test of a specific educational intervention. Readmissions are a lagging, multifactorial outcome, making it difficult to detect a signal from a single process change. The original outcome (skill demonstration) is a much more sensitive and direct measure. Expanding the population to all respiratory diagnoses introduces heterogeneity that would likely obscure, rather than clarify, any effect.\n*   **Verdict:** **Incorrect**.\n\n**D. Execution failure; spread the current paper checklist and leaflet hospital-wide to increase exposure and statistical power, then re-evaluate after $8$ more weeks.**\n*   **Classification:** Correctly identifies the issue as an **execution failure**.\n*   **Proposed Action:** The proposed action is fundamentally flawed. Spreading a process that is known to have failed on a small scale is a recipe for widespread failure and staff burnout. The principle of QI is to test and refine an idea until it works reliably on a small scale *before* spreading it. This proposal does the opposite. The invocation of \"statistical power\" is a misapplication of the concept; the problem is not a small effect size, but a lack of intervention implementation.\n*   **Verdict:** **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Beyond monitoring and improving existing processes, patient safety science involves proactively designing systems to prevent errors before they occur. This advanced practice places you in the role of a safety designer tasked with minimizing risk by making a critical choice in the design of an Electronic Health Record (EHR). By applying principles of constrained optimization, you will synthesize clinical, pharmaceutical, and human factors data to make an evidence-based decision that builds safety into our clinical tools .",
            "id": "5198093",
            "problem": "A pediatric quality improvement team is redesigning an Electronic Health Record (EHR) order to reduce tenfold dosing errors for an analgesic administered to children. Consider a single patient, a child weighing $12~\\mathrm{kg}$, who requires parenteral morphine for acute pain.\n\nFundamental medication and system constraints:\n- Therapeutic intravenous (IV) morphine single-dose range for children: $0.05$ to $0.10~\\mathrm{mg/kg/dose}$, with a maximum single dose of $5~\\mathrm{mg}$.\n- Available stock vial concentration: $2~\\mathrm{mg/mL}$.\n- For peripheral intravenous (PIV) push, pharmacy policy requires dilution to a maximum concentration of $1~\\mathrm{mg/mL}$ before administration.\n- Syringe measurement capabilities: minimum accurate deliverable volume is $0.2~\\mathrm{mL}$, and volumes must be ordered in increments of $0.1~\\mathrm{mL}$.\n- Safety principles to prevent dose-expression errors: do not use trailing zeros, and always use a leading zero for doses less than $1~\\mathrm{mg}$.\n\nProposed EHR order sentence options and their error-risk characteristics (each option is mutually exclusive, and only one will be used):\n- Option A (free-text): decimal point use carries a per-order tenfold overdose probability of $p_{\\mathrm{dec,free}}=2.0\\times 10^{-3}$; if the dose is an integer in milligrams and a trailing zero is used (for example, “$1.0~\\mathrm{mg}$”), the per-order tenfold overdose probability is $p_{\\mathrm{trail}}=5.0\\times 10^{-4}$. Leading zeros are not enforced.\n- Option B (structured order set): leading zeros are enforced and trailing zeros are stripped. If the dose requires a decimal point (i.e., is non-integer in milligrams), the per-order tenfold overdose probability is $p_{\\mathrm{dec,str}}=5.0\\times 10^{-4}$. If the dose is an integer in milligrams, no decimal point is displayed and trailing zeros are not used; in that case, the per-order tenfold overdose probability is $0$.\n\nAssumptions for risk modeling:\n- For a given order, only one mechanism applies: if the numeric value is an integer in milligrams and the sentence format uses no decimal point, the decimal-point error mechanism does not apply. If a trailing zero is present (Option A when an integer is entered as “$x.0~\\mathrm{mg}$”), the trailing-zero mechanism applies. If the dose is non-integer in milligrams (requires a decimal point), the decimal-point mechanism applies according to the option in use.\n- Use only the provided probabilities and do not introduce additional sources of risk. Treat these per-order probabilities as the outcome of well-tested observational data on error mechanisms.\n\nTask:\nUsing only the foundational definition of weight-based dosing (dose equals weight times dose per kilogram) and the above constraints and risk properties, determine the single morphine dose in milligrams that minimizes the per-order tenfold overdose probability while:\n- remaining within the therapeutic range for this $12~\\mathrm{kg}$ child,\n- satisfying the PIV concentration constraint,\n- and complying with the syringe measurement constraints.\n\nIf multiple doses lead to the same minimal risk, choose the midpoint of the therapeutic range expressed in milligrams. Report only the dose in milligrams. Round your answer to one significant figure. Express the final dose in mg. Do not include the EHR option in your final response; only supply the milligram value as requested.",
            "solution": "The task is to find the optimal single dose of morphine for a pediatric patient that minimizes the probability of a tenfold overdose, subject to a set of therapeutic and systemic constraints. This is a constrained optimization problem.\n\nFirst, we must validate the problem statement.\nThe givens are:\n- Patient weight: $W = 12~\\mathrm{kg}$\n- Therapeutic dose range: $0.05$ to $0.10~\\mathrm{mg/kg/dose}$\n- Maximum single dose: $D_{\\mathrm{max}} = 5~\\mathrm{mg}$\n- Stock vial concentration: $C_{\\mathrm{stock}} = 2~\\mathrm{mg/mL}$\n- Required dilution for administration: $C_{\\mathrm{admin}} \\leq 1~\\mathrm{mg/mL}$\n- Minimum accurate deliverable volume: $V_{\\mathrm{min}} = 0.2~\\mathrm{mL}$\n- Syringe volume increments: $\\Delta V = 0.1~\\mathrm{mL}$\n- Option A (free-text) risk probabilities: $p_{\\mathrm{dec,free}} = 2.0 \\times 10^{-3}$ for decimal use, $p_{\\mathrm{trail}} = 5.0 \\times 10^{-4}$ for trailing zero use on an integer dose.\n- Option B (structured) risk probabilities: $p_{\\mathrm{dec,str}} = 5.0 \\times 10^{-4}$ for non-integer doses, $p_{\\mathrm{int}} = 0$ for integer doses.\n\nThe problem is scientifically grounded in pharmacology and patient safety principles, is well-posed with a clear objective and constraints, and is expressed in objective, quantitative terms. There are no contradictions or missing pieces of critical information. Therefore, the problem is valid, and we may proceed with the solution.\n\nThe solution process involves three main steps:\n1. Determine the set of all therapeutically acceptable doses for the patient.\n2. Analyze how systemic constraints (syringe, concentration) affect the choice of dose.\n3. Evaluate the overdose risk for the set of possible doses and identify the dose that minimizes this risk.\n\nStep 1: Determine the therapeutic dose range.\nThe patient weighs $W = 12~\\mathrm{kg}$. The therapeutic dose rate is between $0.05~\\mathrm{mg/kg}$ and $0.10~\\mathrm{mg/kg}$.\nThe minimum therapeutic dose is:\n$$D_{\\mathrm{ther,min}} = 12~\\mathrm{kg} \\times 0.05~\\mathrm{mg/kg} = 0.6~\\mathrm{mg}$$\nThe maximum therapeutic dose is:\n$$D_{\\mathrm{ther,max}} = 12~\\mathrm{kg} \\times 0.10~\\mathrm{mg/kg} = 1.2~\\mathrm{mg}$$\nThe overall maximum single dose is given as $5~\\mathrm{mg}$, which is greater than $D_{\\mathrm{ther,max}}$. Thus, the allowed therapeutic range for this patient is $D \\in [0.6, 1.2]~\\mathrm{mg}$.\n\nStep 2: Analyze systemic constraints.\nThe ordered dose $D$ in milligrams must be administrable. The pharmacy must prepare a volume $V$ from a concentration $C_{\\mathrm{admin}}$ such that $V = D / C_{\\mathrm{admin}}$. The constraints are $C_{\\mathrm{admin}} \\leq 1~\\mathrm{mg/mL}$, $V \\ge 0.2~\\mathrm{mL}$, and $V$ must be a multiple of $0.1~\\mathrm{mL}$.\nFor any dose $D$ in the therapeutic range $[0.6, 1.2]~\\mathrm{mg}$, it is possible for the pharmacy to choose a valid concentration $C_{\\mathrm{admin}}$ and volume $V$. For example, for a dose $D$, one could choose a volume $V'$ that is a multiple of $0.1~\\mathrm{mL}$ and satisfies $V' \\ge D$. This ensures that the required concentration $C_{\\mathrm{admin}} = D/V'$ will be less than or equal to $1~\\mathrm{mg/mL}$. Since all doses $D \\ge 0.6~\\mathrm{mg}$, the condition $V' \\ge D$ also ensures $V' \\ge 0.2~\\mathrm{mL}$.\nTherefore, the administration constraints do not further restrict the set of possible doses from the therapeutic range. The set of possible doses remains the continuous interval $D \\in [0.6, 1.2]~\\mathrm{mg}$.\n\nStep 3: Evaluate risk and find the optimal dose.\nThe objective is to minimize the per-order tenfold overdose probability, $P(\\text{error})$. The problem specifies that the risk depends on the EHR ordering option and whether the dose value in milligrams is an integer. For any given dose $D$, we can choose the EHR option (A or B) that yields the lower risk.\n\nLet's analyze the risk as a function of the dose $D$:\n- Case 1: The dose $D$ is a non-integer value.\n  Any dose $D \\in [0.6, 1) \\cup (1, 1.2]$ is a non-integer. Such a dose requires a decimal point in its representation (e.g., $0.7~\\mathrm{mg}$, $1.2~\\mathrm{mg}$).\n  - With Option A (free-text), the risk is $p_{\\mathrm{dec,free}} = 2.0 \\times 10^{-3}$.\n  - With Option B (structured), the risk is $p_{\\mathrm{dec,str}} = 5.0 \\times 10^{-4}$.\n  The minimum risk for any non-integer dose is achieved with Option B, so $P(\\text{error} | D \\text{ is non-integer}) = 5.0 \\times 10^{-4}$.\n\n- Case 2: The dose $D$ is an integer value.\n  We must check if any integer values fall within the therapeutic range $D \\in [0.6, 1.2]~\\mathrm{mg}$. The only integer in this interval is $D=1$.\n  - With Option A (free-text), an integer dose can be entered with a trailing zero (e.g., \"$1.0~\\mathrm{mg}$\"), which carries a risk of $p_{\\mathrm{trail}} = 5.0 \\times 10^{-4}$. The system allows for this user error.\n  - With Option B (structured), an integer dose is displayed without a decimal point, and the risk is explicitly stated as $p_{\\mathrm{int}} = 0$.\n  The minimum risk for an integer dose is achieved with Option B, so $P(\\text{error} | D=1) = 0$.\n\nComparing the minimum achievable risks, we have:\n$$ P(\\text{error}) = \\begin{cases} 0 & \\text{if } D=1~\\mathrm{mg} \\\\ 5.0 \\times 10^{-4} & \\text{if } D \\in [0.6, 1) \\cup (1, 1.2] \\end{cases} $$\nThe global minimum risk is $0$, which is uniquely achieved at the dose $D = 1~\\mathrm{mg}$. Since this dose is unique, the tie-breaker rule is not invoked.\n\nThe optimal dose is $1~\\mathrm{mg}$. The problem requires the answer to be rounded to one significant figure. The number $1$ has one significant figure.\nTherefore, the final answer is $1$.",
            "answer": "$$\n\\boxed{1}\n$$"
        }
    ]
}